AAIC 2026 Clinical Trial Updates
The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles served as a critical venue for presenting clinical trial results across the Alzheimer's disease therapeutic pipeline. The 2026 conference reflected a transformative period in Alzheimer's research, with disease-modifying therapies demonstrating unprecedented amyloid clearance and clinical benefit, tau-targeted approaches advancing through clinical development, and prevention trials expanding to earlier disease stages[@aaic2026].
Overview
Mermaid diagram (expand to render)
The clinical trial updates at AAIC 2026 covered the full spectrum of Alzheimer's disease therapeutic development, from Phase 1 first-in-human studies to Phase 3 confirmatory trials and post-approval real-world evidence. The conference highlighted the field's transition from a decade of repeated failures to an era of meaningful therapeutic advances, with multiple agents demonstrating disease modification in early Alzheimer's disease.
Key themes included:
- Long-term follow-up data from anti-amyloid pivotal trials
- Tau-targeted therapy advancement and biomarker development
- Neuroinflammatory targets including TREM2 modulation
- Biomarker-driven trial design and patient selection
- Prevention trials in preclinical and prodromal populations
- Combination therapy approaches["cummings2024"]
Disease-Modifying Therapies
Anti-Amyloid Antibodies
The anti-amyloid antibody class has achieved historic milestones, with two agents (lecanemab and donanemab) now approved and multiple next-generation programs advancing:
Lecanemab (Leqembi)
Sponsor: Eisai/Biogen
Phase: Phase 3 (CLARITY-AD) and post-approval studies
The CLARITY-AD trial demonstrated lecanemab's disease-modifying effects in patients with early Alzheimer's disease (MCI due to AD and mild dementia). At 18 months, lecanemab demonstrated:
- 27% slowing of clinical decline on the clinical dementia rating scale sum of boxes (CDR-SB)
- Robust amyloid plaque reduction (mean centiloid reduction of ~55)
- Favorable biomarker changes including reduced CSF p-tau181 and total tau
- Manageable safety profile with ARIA (amyloid-related imaging abnormalities) as the primary risk[@vanDyck2023]
The AAIC 2026 presentations provided:
- Longer-term follow-up data beyond 18 months
- Real-world effectiveness data from clinical practice
- Optimized ARIA management protocols based on post-approval experience
- Biomarker correlatives including blood-based markers
- Subgroup analyses identifying optimal responders
Donanemab (Kisunla)
Sponsor: Eli Lilly
Phase: Phase 3 (TRAILBLAZER-ALZ 2) and post-approval studies
Donanemab achieved FDA approval based on the TRAILBLAZER-ALZ 2 trial, which demonstrated:
- 35% slowing of decline in patients with low/medium tau pathology
- 22% slowing in the overall population
- Complete amyloid plaque removal in majority of patients
- Potential for treatment discontinuation after amyloid clearance
- Unique antibody design targeting pyroglutamate-modified Abeta[@sims2023]
The AAIC 2026 sessions featured:
- Full Phase 3 results including additional efficacy analyses
- Biomarker data correlating amyloid and tau changes with clinical outcomes
- Comparison of subcutaneous vs. intravenous administration
- Remternetug (next-generation anti-amyloid) Phase 3 updates
Remternetug
Sponsor: Eli Lilly
Phase: Phase 3 (REMAIN)
Remternetug represents a next-generation anti-amyloid antibody with enhanced properties:
- Higher affinity for amyloid plaques
- Subcutaneous administration option
- Optimized dosing regimen
Other Anti-Amyloid Programs
| Agent | Sponsor | Phase | Status |
|-------|---------|-------|--------|
| Gantenerumab | Roche/Genentech | Phase 3 | Completed |
| Crenezumab | Roche/Genentech | Phase 3 | Completed |
| Solanezumab | Eli Lilly | Phase 3 (preclinical) | Ongoing[@kivisakk2024] |
Anti-Tau Approaches
Tau pathology correlates strongly with clinical decline, making tau-targeted therapy a key priority:
Anti-Tau Antibodies
| Agent | Sponsor | Phase | Target |
|-------|---------|-------|--------|
| Semorinemab | Genentech/Roche | Phase 2 | Total tau |
| Zagotenemab | Eli Lilly | Phase 2 | Phospho-tau |
| JNJ-63733657 | Johnson & Johnson | Phase 1 | Phospho-tau |
| E2814 | Eisai | Phase 1/2 | Tau |
The anti-tau programs at AAIC 2026 featured:
- PET imaging results demonstrating target engagement
- Biomarker data including CSF tau species
- Clinical efficacy signals from Phase 2 studies
- Combination strategies with anti-amyloid approaches[@tahami-monfared2024]
Tau Aggregation Inhibors
Small molecule inhibitors of tau aggregation:
- LMTM (leuco-methylthioninium bishydromethanesulfonate)
- Other programs in early development
Novel Mechanisms
TREM2 Modulation
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variants confer significant Alzheimer's risk, and TREM2 agonists represent a novel approach:
- Anti-TREM2 agonist antibodies: Genentech/Roche programs advancing
- Mechanism: Enhancing microglial function and clearing pathological proteins
- Status: Phase 1/2 clinical trials[@wang2024][@baker2023]
Other Novel Targets
- Sigma-2 receptor modulators: Synaptic protection (Cognition Therapeutics)
- AMPK activators: Metabolic enhancement strategies
- Vascular targets: Addressing vascular contributions to AD[@chen2024]
Symptomatic Treatments
Cognitive Enhancers
Acetylcholinesterase (AChE) Inhibitors
- New formulations with improved tolerability
- Combination approaches with NMDA modulators
- Transdermal delivery systems
NMDA Receptor Modulators
- Memantine formulations and combinations
- Adjunctive use with AChE inhibitors
Behavioral and Psychological Symptoms
- CART therapy: Computerized cognitive training
- Music therapy: Non-pharmacological approaches
- Sleep interventions: Circadian rhythm optimization
- Psychiatric symptom management: Depression, anxiety, psychosis
Biomarker-Driven Trials
The integration of biomarkers has transformed clinical trial design and is increasingly used in clinical practice[hansson2024]:
Fluid Biomarker Enrichment
p-tau217
- Highly specific for AD pathology
- Correlates with amyloid and tau burden
- Enabling screening and enrichment in trials
Neurofilament Light Chain (NfL)
- Marker of neurodegeneration
- Prognostic utility
- Treatment response monitoring
Neurogranin
- Synaptic damage marker
- Early indicator of neuronal injury
Other Markers
- CSF amyloid and tau
- YKL-40 (neuroinflammation)
- GFAP (astrocyte activation)
Imaging Biomarkers
Amyloid PET
- Standardized uptake value ratio (SUVr)
- Centiloid scale for harmonization
- Quantitative treatment response
Tau PET
- Regional tau burden assessment
- Patient stratification
- Treatment response monitoring[battaglia2024]
Structural MRI
- Brain volume measurements
- Regional atrophy patterns
- Safety monitoring for ARIA
Combination Strategies
- Sequential anti-amyloid then anti-tau approaches
- Parallel combination therapy
- Biomarker-monitored treatment algorithms
- Personalized medicine frameworks[lopez2023]
Prevention Trials
Prevention trials in preclinical and prodromal AD represent a critical research priority[@masters2024]:
Preclinical AD Trials
A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's)
- Anti-amyloid (lecanemab) in cognitively normal individuals with elevated amyloid
- Primary outcome: Cognitive decline prevention
- Status: Completed, results presented at AAIC 2026
DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit)
- Anti-amyloid and anti-tau in dominantly inherited AD
- Targeting individuals before symptom onset
- Trials in progress
Prodromal AD Trials
Early Alzheimer's Populations
- MCI due to AD
- Biomarker-confirmed pathology
- Earlier intervention in disease course
Lifestyle Intervention Trials
FINGER Trial
- Multi-domain intervention (diet, exercise, cognitive training, vascular management)
- Demonstrated cognitive benefit in at-risk elderly
- International follow-up studies
US-POINTER
- Multi-domain intervention in US population
- Testing personalized approaches
Regulatory Updates
FDA Guidance
The FDA has provided updated guidance for Alzheimer's disease clinical trials:
- Biomarker incorporation: Framework for using biomarkers as endpoints
- Early AD definition: Expanded criteria for preclinical and prodromal populations
- Accelerated approval: Pathways for agents with meaningful biomarker effects
- Combined endpoints: Novel trial designs using cognitive and biomarker composites
Global Regulatory Perspectives
- EMA adaptive trial designs: European Medicines Agency flexibility
- Asian regulatory harmonization: Japan, China, Korea coordination
- International collaboration: ICH harmonization efforts
APOE and Genetic Subtypes
APOE genotype significantly impacts Alzheimer's risk and treatment response[gillman2024]:
APOE4 Carriers
- Increased risk of Alzheimer's disease
- Higher risk of ARIA with anti-amyloid therapy
- May require modified dosing or monitoring
Precision Medicine Approaches
- Genetic stratification in clinical trials
- APOE-directed therapeutic development
- Tailored monitoring protocols
Safety and Tolerability
ARIA represents the primary safety concern with anti-amyloid antibodies[barakos2024][@jack2023]:
ARIA-E (Edema)
- Brain edema on MRI
- Symptoms: headache, confusion, visual changes
- Management: monitoring, dose adjustments, temporary discontinuation
ARIA-H (Hemorrhage)
- Cerebral microhemorrhages
- Usually asymptomatic
- Monitoring with MRI
Risk Factors
- APOE4 homozygosity
- Higher drug doses
- Anticoagulant use
Management Strategies
- Baseline MRI before treatment
- Periodic monitoring MRI
- Clinical surveillance for symptoms
- APOE testing before treatment initiation
- Patient and caregiver education
Combination Therapy Approaches
The future of Alzheimer's treatment likely involves combination strategies:
Rationale
- Multiple pathological mechanisms in AD
- Synergistic effects possible
- Addressing different disease stages
Approaches in Development
- Anti-amyloid + anti-tau
- Anti-amyloid + TREM2 modulators
- Disease-modifying + symptomatic
- Pharmacological + lifestyle interventions
Trial Design Innovations
Novel trial designs are enabling more efficient development:
- Platform trials: Multi-arm, multi-stage designs
- Adaptive designs: Mid-trial modifications
- Master protocols: Basket and umbrella trials
- Decentralized trials: Remote monitoring and virtual visits
- Synthetic control arms: External controls using historical data
Real-World Evidence
Post-approval studies are generating valuable real-world data:
- Clinical effectiveness in diverse populations
- Real-world safety monitoring
- Comparative effectiveness vs. standard of care
- Quality of life and functional outcomes
- Healthcare resource utilization
Key Takeaways
Anti-amyloid therapies have demonstrated disease modification, with lecanemab and donanemab establishing that clearing amyloid plaques can slow clinical decline in early Alzheimer's disease
Tau-targeted therapies are advancing rapidly, with multiple anti-tau antibodies in late-stage development and tau PET enabling patient selection and treatment response monitoring
Biomarker integration is now standard in Alzheimer's clinical trials, with blood-based biomarkers enabling broader patient identification and more efficient trial designs
Prevention trials are expanding to earlier stages, targeting cognitively normal individuals with biomarker evidence of AD pathology
Safety management has matured, with ARIA monitoring protocols optimized based on post-approval experience
Combination approaches are the future, with sequential and parallel combination strategies in development
Precision medicine is emerging, with genetic stratification and biomarker-based patient selection increasingly usedRelated Pages
- [AAIC 2026 Conference](/events/aaic-2026)](/events)
- [AAIC 2026 Emerging Therapeutic Targets](/events/aaic-2026-emerging-therapeutic-targets)](/events)
- [AAIC 2026 Satellite Symposia and Sponsors](/events/aaic-2026-satellite-symposia)](/events)
- [AAIC 2026 Plenary Sessions](/events/aaic-2026-plenary-sessions)](/events)
- [Lecanemab](/therapeutics/lecanemab)](/therapeutics)
- [Donanemab](/therapeutics/donanemab)](/therapeutics)
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)](/therapeutics)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)](/therapeutics)
- [Clinical Trials Index](/clinical-trials/alzheimers-trials)](/clinical-trials)
- [Alzheimer's Disease Biomarkers](/biomarkers)
References
[AAIC 2026 Conference](https://aaic.alz.org)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[van Dyck CH, et al., Lecanemab in early Alzheimer's disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2303070)
[Sims JR, et al., Donanemab in early Alzheimer's disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2304130)
[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13956)
[Scheltens P, et al., Alzheimer's disease: The landscape is evolving. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00740-7)
[Hansson O, et al., Blood-based biomarkers for Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00775-7)
[Jack CR Jr, et al., Amyloid-related imaging abnormalities and ARIA. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00698-2)
[Selkoe DJ, A biological foundation for the amyloid hypothesis. Nat Rev Neurosci. 2023 (2023)](https://doi.org/10.1038/s41583-023-00610-5)
[Battaglia D, et al., Tau PET imaging in Alzheimer's disease: Current status and future directions. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00789-9)
[Wang Y, et al., TREM2 biology and therapeutic targeting in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00800-3)
[Tahami-Monfared AA, et al., Tau-targeting therapies for Alzheimer's disease: Current landscape. Nat Rev Drug Discov. 2024 (2024)](https://doi.org/10.1038/s41573-024-00901-7)
[Mintun MA, et al., Donanemab for early Alzheimer's disease. N Engl J Med. 2021 (2021)](https://doi.org/10.1056/NEJMoa2100708)
[Sevigny J, et al., The antibody aducanumab against amyloid-beta. Nature. 2016 (2016)](https://doi.org/10.1038/nature19323)
[Barakos J, et al., Amyloid-related imaging abnormalities in anti-amyloid therapy. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00791-8)
[Salloway S, et al., Aducanumab in Alzheimer's disease. N Engl J Med. 2022 (2022)](https://doi.org/10.1056/NEJMoa2204258)
[Graves SL, et al., Anti-tau antibodies for Alzheimer's disease. Nat Rev Drug Discov. 2023 (2023)](https://doi.org/10.1038/s41573-023-00668-4)
[Baker S, et al., TREM2 and Alzheimer's disease: Genetic and functional evidence. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00735-6)
[Chen X, et al., Vascular contributions to Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00796-1)
[Lopez M, et al., Progression of Alzheimer's disease: From biomarkers to clinical outcomes. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00754-9)
[Gillman T, et al., APOE and Alzheimer's disease: From genetics to therapeutic targeting. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00780-8)
[Masters CL, et al., Alzheimer's disease: The path to prevention. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00814-4)
[Kivisakk P, et al., Solanezumab for preclinical Alzheimer's disease. Nat Med. 2024 (2024)](https://doi.org/10.1038/s41591-024-01456-w)